Vanguard Personalized Indexing Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,439	Closed	-$380K	–	1358
2022 Q3	$380K	Buy	5,439 +596	+12%	+$44.1K	0.02%	878
2022 Q2	$325K	Buy	4,843 +1,658	+52%	+$105K	0.02%	960
2022 Q1	$262K	Buy	+3,185	New	+$326K	0.01%	1036
2021 Q4	–	Sell	-1,287	Closed	-$228K	–	1121
2021 Q3	$228K	Sell	1,287 -259	-17%	-$41.7K	0.02%	882
2021 Q2	$250K	Buy	+1,546	New	+$248K	0.03%	810

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Personalized Indexing Management's MRTX Position: Q4 2022 in Review

Vanguard Personalized Indexing Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2022, closing a stake of 5,439 shares — an estimated $380K sold.

Vanguard Personalized Indexing Management first reported a position in MRTX in Q2 2021 and held it in 5 quarters. The position peaked at $380K in Q3 2022. 233 funds tracked by Wall St. Rank hold MRTX as of Q4 2022.

Vanguard Personalized Indexing Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Vanguard Personalized Indexing Management sold 5,439 Mirati Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $380K.
Vanguard Personalized Indexing Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
Vanguard Personalized Indexing Management's Mirati Therapeutics, Inc. Common Stock position peaked at $380K in Q3 2022.
233 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Vanguard Personalized Indexing Management's 13F filing for Q4 2022, filed 10 Feb 2023.